Variation in the CYP2D6 gene is associated with a lower serum sodium concentration in patients on antidepressants.
OBJECTIVE
To study the effect of the CYP2D6*4 polymorphism on serum sodium concentration in users of antidepressants [selective serotonin reuptake inhibitors and tricyclic antidepressants (TCAs)].


METHODS
In this population-based cohort study, all subjects in the Rotterdam Study were included who used an antidepressant at baseline and from whom a blood sample was available in which CYP2D6 genotype and serum sodium concentration could be determined (n= 76). Multivariate linear regression was used to study the association between CYP2D6*4 and serum sodium concentration.


RESULTS
CYP2D6 poor metabolizers (PMs) (*4/*4) had a significantly lower mean serum sodium concentration in comparison with CYP2D6 extensive metabolizers (EMs) (*1/*1) [difference -3.9 mmol l(-1); 95% confidence interval (CI) -0.86, -7.03; P= 0.013]. In CYP2D6*4 heterozygotes (*1/*4) serum sodium concentration was 1.7 mmol l(-1) (95% CI -3.48, 0.18) lower compared with CYP2D6 EMs, but this difference was not statistically significant (P= 0.077).


CONCLUSIONS
The serum sodium concentration in PMs was lower in users of an antidepressant, especially in TCA users. Therefore CYP2D6 PMs might be at increased risk of developing symptoms of hyponatraemia.
Kwadijk-de Gijsel
Sonja
S
Department of Hospital Pharmacy, Erasmus Medical Centre, Rotterdam 3000 CA, The Netherlands.
Bijl
Monique J
MJ
Visser
Loes E
LE
van Schaik
Ron H N
RH
Hofman
Albert
A
Vulto
Arnold G
AG
van Gelder
Teun
T
Ch Stricker
Bruno H
BH
D000368:Aged; D000928:Antidepressive Agents / Q000493:pharmacokinetics* / Q000627:therapeutic use; D015331:Cohort Studies; D019389:Cytochrome P-450 CYP2D6 / Q000235:genetics* / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D016903:Drug Monitoring; D005260:Female; D005838:Genotype; D006801:Humans; D007010:Hyponatremia / Q000139:chemically induced / Q000378:metabolism*; D008297:Male; D011110:Polymorphism, Genetic / Q000187:drug effects / Q000235:genetics
D000928:Antidepressive Agents; D019389:Cytochrome P-450 CYP2D6
J Clin Psychopharmacol. 1984 Jun;4(3):146-7
6429213
Arq Neuropsiquiatr. 2006 Mar;64(1):142-5
16622573
N Engl J Med. 2000 May 25;342(21):1581-9
10824078
Mol Psychiatry. 2004 May;9(5):442-73
15037866
Br J Clin Pharmacol. 2008 Apr;65(4):558-64
18070221
Eur J Epidemiol. 2007;22(11):819-29
17955331
Am J Psychiatry. 1997 Apr;154(4):580
9090354
Am J Psychiatry. 1989 Jun;146(6):807
2729439
Eur J Epidemiol. 1991 Jul;7(4):403-22
1833235
Am J Med. 2006 Jan;119(1):71.e1-8
16431193
Hum Psychopharmacol. 2002 Jun;17(4):187-90
12404686
Eur J Clin Pharmacol. 2002 May;58(2):143-8
12012148
J Palliat Med. 2006 Apr;9(2):258-60
16629552
Nurse Pract. 2008 Feb;33(2):11-2
18300778
Am J Kidney Dis. 2006 Oct;48(4):e61-2
16997047
Pharmacogenomics. 2002 Mar;3(2):229-43
11972444
N Engl J Med. 2005 May 26;352(21):2211-21
15917386
Nephrol Dial Transplant. 2006 Jan;21(1):70-6
16141458
Ann Pharmacother. 2006 Sep;40(9):1618-22
16896026